Biopharmaceutical company Zai Lab Ltd. raised HK$6.61 billion ($825 million) on its secondary listing in Hong Kong Monday, as it became the latest U.S.-listed Chinese company to start trading closer to home amid growing Wall Street wariness.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
